Study Summary
PACMAN is a phase I/II single arm, open-label, multi-center study evaluating the safety of human CD19 CAR-T (huCAR19) produced locally using the Miltenyi Prodigy in children, adolescents and young adults with relapsed/refractory CD19+ hematological malignancies for whom no standard of care treatment is available.
Want to learn more about this trial?
Request More InfoInterventions
CAR T-cell and Cellular TherapiesOTHER
A single IV infusion of huCAR 19 T-cells on day 0. In phase I 3 dose levels are tested to determine the RP2D.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University Medical Center Utrecht | Utrecht | Utrecht | Netherlands |
| Princess Máxima Center for pediatric oncology | Utrecht | Utrecht | Netherlands |